Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2003-07-04
2010-06-01
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100
Reexamination Certificate
active
07727526
ABSTRACT:
The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.
REFERENCES:
patent: 6903194 (2005-06-01), Sato et al.
patent: 1 197 225 (2002-04-01), None
patent: 1197225 (2002-04-01), None
patent: 1 283 057 (2003-02-01), None
patent: WO 96/22790 (1996-08-01), None
patent: WO 97/04312 (1997-02-01), None
patent: WO 01/85784 (2001-11-01), None
Hoare, S.R.J. and Usdin, T.B. Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39). Peptides, 2002. vol. 23, pp. 989-998.
Bachmann, M.F., Wolint, P., Schwarz, K., and Oxenius, A. Recall proliferation potential of memory CD8+ T cells and antiviral protection. 2005, Journal of Immunology, vol. 175, pp. 4677-4685.
Burton, P.B.J., Moniz, C., and Knight, D. Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma. 1990, Biochemical and biophysical research communications, vol. 167, No. 3, pp. 1134-1138.
Efferson, C.L., Kawano, K., Tsuda, N., Palese, P., Garcia-Sastre, A., and Ioannides, C.G. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2
eu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. 2005, Anticancer Research, vol. 25, pp. 715-724.
Wheeler, C.M. Preventive vaccines for cervical cancer. 1997. Salud Publica de Mexico, vol. 39, No. 4, pp. 1-9.
Drucker, B.J. Renal Cell Carcinoma: Current status and future prospects, 2005. Cancer Treatment Reviews, vol. 31, pp. 536-545.
Iwamura, M., Wu, W., Muramoto, M., Ohori, M., Egawa, S., Uchida, T., and Baba, S. Parathyroid hormone-related protein is an independent prognostic factor for renal cell carcinoma. Cancer, 1999. vol. 86 No. 6, pp. 1028-1034.
Massfelder, Lang, Schordan, Kinder, Rothhut, Welsch, Simon-Assmann, Barthelmebs, Jacqmin, and Helwig. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Research, 2004. vol. 64, pp. 180-188.
Burton et al, Biochemical and Biophysical Research Communications, 1990, vol. 167, No. 3, pp. 1134-1138.
Savage et al, Journal of Endocrinology, 1993, vol. 137, No. suppl., p. P57.
Hoare et al, Peptides, 2002, vol. 23, No. 5, pp. 989-998.
Akino et al, Endocrinology, 2000, vol. 141, No. 11, pp. 4313-4316.
Luparello et al, “Midregion Parathyroid Hormone-Related Protein Inhibits Growth and Invasion In Vitro and Tumorigenesis In Vivo of Human Breast Cancer Cells”, Journal of Bone and Mineral Research, 2001, vol. 16, No. 12, pp. 2173-2181.
Esaki et al “The selection of therapeutic antibodies by kenetic analysis” Biocore Journal—No. 2 2002, pp. 7-8)) obtained from a hybridoma (such as the hybridoma #23-57-137-1.
Okada et al “Immunohistochemical Localization of Parathyroid Hormone-related Protein in Canine Mammary Tumors” Vet Pathol 34: 356-359 (1997).
Verheijen et al, “Parathyroid hormone-related peptide (PTHrP) induces parietal endoderm formation exclusively via the Type I PTH/PTHrP receptor” Mechanisms of Development 81 (1999) 151-161.
Thorikay et al., “Synthesis of a gene encoding parathyroid hormone-like protein-(1-141): purification and biological characterization of the expressed protein” Endocrinology, vol. 124, 111-118 (1989).
Fenton et al., “A carboxyl-terminal peptide from the parathyroid hormone-related protein inhibits bone resorption by osteoclasts.” Endocrinology. Oct. 1991;129(4):1762-8 (Abstract).
Santos et al “Up-regulation of parathyroid hormone-related protein in folic acid-induced acute renal failure” Kidney International, vol. 60 (2001), pp. 982-995.
Garcia-Ocana et al “Cyclosporine increases renal parathyroid hormone-related protein expression in vivo in the rat” transplantation, vol. 65, 860-863, No. 6, Mar. 27, 1998.
Richard, et al. “Humoral Hypercalcemia of Malignancy, Severe Combined Immunodeficient/Beige Mouse Model of Adult T-Cell Lymphoma Independent of Human T-Cell Lymphotropic Virus Type-1 Tax Expression” Am J Pathol. Jun. 2001; 158(6): 2219-2228.
Helwig Jean-Jacques
Lang Herve
Massfelder Thierry
Schordan Eric
Gussow Anne M.
Helms Larry R.
Hopitaux Universitaires de Strasbourg
Institut National de la Sante et de la Recherche Medicale (INSER
Nixon & Vanderhye P.C.
LandOfFree
Use of PTHrP antagonists for treating renal cell carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of PTHrP antagonists for treating renal cell carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of PTHrP antagonists for treating renal cell carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242046